Deal Tracker · Countries

UAE pharma licensing deals

12 licensing deals involving UAE tracked by EPT (2023–2026). Most active: ADCAN Pharma, Arcera Life Sciences, Elpen & Alvion Pharmaceuticals. Latest: Innogen Pharmaceuticals → Arcera Life Sciences (Licensing, 19 Nov 2026).

12
deals tracked
10
announced in 2026
$694m
disclosed value (2 deals)
100%
licensing, the top deal type
  • EPT has tracked 12 UAE pharma licensing deals (2023–2026), 10 of them announced in 2026.
  • The countries that appear most often are Saudi Arabia (7), Greece (3), China (2) & India (2).
  • Values were disclosed for 2 of 12 deals, totalling $694m; the largest is AriBio → Arcera Life Sciences ($600m, 10 Jun 2025).
  • The most active companies: ADCAN Pharma (7), Arcera Life Sciences (3) & Elpen (2).

Most active companies

ADCAN Pharma (7) · Arcera Life Sciences (3) · Elpen (2)

Countries involved

Saudi Arabia (7) · Greece (3) · China (2) · India (2) · Iraq (2) · South Korea (2)

Largest disclosed deals

Questions

How many UAE pharma licensing deals has EPT tracked?
12 as of 19 Nov 2026, covering 2023–2026; 10 were announced in 2026. The most recent is Innogen Pharmaceuticals → Arcera Life Sciences (Licensing, 19 Nov 2026).
Which companies are most active in UAE pharma licensing deals?
ADCAN Pharma (7 deals), Arcera Life Sciences (3 deals), Elpen (2 deals).
What is the largest disclosed UAE pharma licensing deal?
AriBio → Arcera Life Sciences: $600m (Licensing, 10 Jun 2025); Daewoong Pharmaceutical → Arcera Life Sciences: $94m (Licensing, 29 Jun 2026). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)